ten23 health presents its fairstainability impact report

ten23 health the human-centric and sustainable strategic contract development, testing and manufacturing organization in the pharmaceutical sector (CDTMO), and partner of choice for the pharmaceutical industry and biotech start-ups, is proud to announce a range of achievements and sustainability certifications.

ten23’s latest Fairstainability impact report for the full year 2024 follows the Voluntary Sustainability Reporting for non-listed SMEs (VSME) disclosure standard to further enhance transparency on the environmental, social and governance (ESG) activities of the company, and provide a holistic and comprehensive view of its sustainability initiatives.

Highlights

• 57% reduction in Scope 1 and 2 GHG emissions by revenue compared to the 2021 baseline (achieving its 2025 goal one year early)
• SBTi validation for its science-based climate targets and completion of its double materiality assessments. This marks a significant milestone in the company’s Fairstainability program, which is aligned with global efforts to limit warming to 1.5°C above pre-industrial levels. The SBTi targets include a short-term goal of a 42% reduction in GHG emissions by 2030 (fusing 2023 as the base year) and a net-zero target of reducing Scope 1, 2, and 3 emissions by at least 90% by 2050 or earlier.
• Earning the highest certification level (Green) from MyGreen Lab for its Basel development labs, with an outstanding overall score of 88.
• An EcoVadis score of 73 in 2025, placing ten23 in the top 3% of companies in the manufacture of pharmaceutical products and pharmaceutical preparations which are rated by EcoVadis.
• These achievements are alongside ten23 becoming the first sterile drug product CDMO to achieve B Corp certification, which was announced in August 2024.

“All the actions and achievements in the report together with our focus on collaboration, underscore ten23 health's unwavering commitment to fostering a culture of sustainability in the Pharma sector. They reflect the organization's dedication to adopting and innovating eco-friendly practices and reducing the environmental impact of its operations and value chain. These accomplishments also reinforce ten23 health's commitment to holistic, tangible, science-driven environmental action,” said Alissa Monk, Co-Fairstainability Lead, ten23 health.

As ten23 health celebrates these achievements, it remains steadfast in its mission to create a materially positive impact on society and the environment. These milestones signify the company’s leadership in driving change towards a more sustainable future.

“The SBTi approval and certifications with MyGreen Lab and Ecovadis are significant milestones for ten23 health. They reaffirm our company’s dedication, leadership role and ambition to leave a heartprint in sustainable business in the Pharma and CDMO sector,” commented Hanns-Christian Mahler, CEO of ten23 health.